2024 ANNUAL RESULTS Growth of core business and strategic execution Revenue up 19% to €154 million Organic growth at +9%Proprietary products account for a stable 31% of group revenueInternational accounts for 41% of group revenue Stable 2024 operational results, reflecting pressure on margins and underperformance of some European subsidiariesFree cash flow of €6 millionNet debt of €3.9 million, including EB Development current account Paris, April 28, 2024 - 5:40 pm - Eurobio Scientific (FR0013240934, ALER ...